DEA Revokes De Novo Services' Drug Handling License Over Decade of Sloppiness
Published Date: 4/23/2025
Notice
Summary
De Novo Services, LLC lost its DEA registration because it didn’t keep good control over controlled substances and broke recordkeeping rules from 2013 to 2023. Since they didn’t ask for a hearing, the DEA decided to revoke their registration, meaning they can’t legally handle these drugs anymore. This affects De Novo directly and signals a strict stance on drug safety and record rules.
Analyzed Economic Effects
3 provisions identified: 1 benefits, 2 costs, 0 mixed.
DEA Registration Revoked for De Novo
De Novo Services, LLC (DEA Certificate No. RD0424515) had its DEA registration revoked for failures to control and account for controlled substances between 2013 and 2023. Because De Novo did not request a hearing, the DEA entered a final order revoking the registration effective May 23, 2025.
Pending Renewal and New Applications Denied
The DEA denied any pending applications by De Novo Services, LLC to renew or modify its registration and denied any other pending application by De Novo for additional registration in Utah. Those denials accompany the revocation order and are part of the final agency action.
Final Adjudication Creates Public Record and Deterrence
The DEA adjudicated this matter to finality to create an official public record to educate current and prospective registrants about their responsibilities and to inform stakeholders of the Agency's enforcement priorities. The decision states that specific and general deterrence weighed in favor of revocation.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526 — Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128 — Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2026-11909 — Importer of Controlled Substances Application: Cerilliant Corporation
Cerilliant Corporation wants to become an official importer of certain controlled substances, including some drugs that need strict government oversight. People and companies involved with these substances can share their thoughts or ask for a hearing by July 15, 2026. This move could affect how these drugs enter the U.S. and might impact businesses handling them.
2026-11572 — Ashley Vermillion, N.P.; Decision and Order
Ashley Vermillion, a nurse practitioner from Maine, lost her DEA registration because she no longer has the legal right to handle controlled substances in her state. She didn’t ask for a hearing, so the DEA moved forward and officially revoked her registration. This means she can’t prescribe or manage controlled drugs anymore, effective immediately.
2026-11416 — Importer of Controlled Substances Application: CalCog Inc.
CalCog Inc. wants to become an official importer of some powerful controlled substances like LSD and 5-MeO-DMT. People and companies involved with these drugs have until July 8, 2026, to share their thoughts or ask for a hearing. This move could shake up the import scene, but no costs or changes happen until the DEA decides.
2026-10380 — Schedules of Controlled Substances: Placement of Diphenidine in Schedule I
The DEA wants to put diphenidine, a drug, into Schedule I, which means it will be treated like the most tightly controlled substances. This change affects anyone who makes, sells, studies, or owns diphenidine, adding strict rules and penalties. You’ve got until June 25, 2026, to share your thoughts before the new rules might kick in.
Previous / Next Documents
Previous: 2025-07025 — Extension of Agency Information Collection Activity Under OMB Review: Enhanced Security Procedures at Ronald Reagan Washington National Airport
The TSA is asking to keep collecting info from small plane pilots and armed security officers at Ronald Reagan Washington National Airport. Pilots need to pick a security coordinator and follow special safety rules. This helps keep everyone safe without adding extra costs or delays.
Next: 2025-07029 — Draft Aquaculture Opportunity Area Options-Alaska State Waters
NOAA is exploring spots in Alaska’s state waters where fish farms could grow and thrive, aiming to boost local seafood business and jobs. They’ve picked some draft areas and want your thoughts before making final decisions. This is a big step toward smarter, eco-friendly aquaculture, with public input shaping the future and no money changes yet.